还可以E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration.
为众多的药物研发团队赋能，
让新药发现更简单！
还可以E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 2 mg | ¥ 15,600 | 5日内发货 | |
| 5 mg | ¥ 24,100 | 5日内发货 | |
| 25 mg | ¥ 33,800 | 8-10周 | |
| 50 mg | ¥ 51,200 | 8-10周 | |
| 100 mg | ¥ 75,500 | 8-10周 | |
| 1 mL x 10 mM (in DMSO) | ¥ 29,500 | 5日内发货 |
客户已引用 客户已引用 
客户已引用 客户已引用 | 产品描述 | E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration. |
| 体外活性 | E6130 also shows agonistic activity via CX3CR1 with respect to GTPγS binding (EC50 = 133 nM) and β-arrestin recruitment (EC50 = 2.4 μM) in CX3CR1-expressing CHO-K1 membrane but show no antagonistic activity.E6130 is an orally available and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis of human peripheral blood natural killer cells (IC50, 4.9 nM), and down-regulates CX3CR1 on the cell surface of CD56+ NK cells with an EC50 value of 5.2 nM. |
| 体内活性 | E6130(10 or 30mg /kg, p.o.) reduced some parameters associated with inflammatory bowel disease in a mouse model of CD4+ CD45RBhigh t cell metastatic colitis and a mouse model of oxazolidin-induced colitis. |
| 分子量 | 556.06 |
| 分子式 | C28H37ClF3N3O3 |
| CAS No. | 1427058-33-0 |
| 密度 | 1.31 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 250 mg/mL (449.59 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
嗨！有任何问题？点我咨询
比如您的给药剂量是 10 mg/kg ，每只动物体重 20 g ，给药体积 100 μL ， 
评论内容